Intestinal neuroendocrine neoplasm
MONDO:0002883A neoplasm with neuroendocrine differentiation that arises from the small or large intestine. It includes well differentiated neuroendocrine tumors (low and intermediate grade) and poorly differentiated neuroendocrine carcinomas (high grade).
Also known as: intestinal neuroendocrine neoplasm, intestine NET, intestine neuroendocrine neoplasm, intestine neuroendocrine tumor, intestine neuroendocrine tumor, well differentiated, low or intermediate grade, intestine neuroendocrine tumour, neuroendocrine neoplasm of intestine, neuroendocrine neoplasm of the intestine
1489 clinical trials for this condition and its sub-types, 7 tagged with Intestinal neuroendocrine neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Intestinal neuroendocrine neoplasm
-
Small intestine neuroendocrine neoplasm 0 trials · 9 incl. sub-types
3 sub-types
- Small intestine neuroendocrine tumor, well differentiated, low or intermediate grade 4 trials · 9 incl. sub-types Sub-types →
- Duodenal neuroendocrine neoplasm 0 trials Sub-types →
- Hereditary neuroendocrine tumor of small intestine 0 trials
-
Intestinal neuroendocrine tumor G1 5 trials · 8 incl. sub-types
2 sub-types
- Small intestinal neuroendocrine tumor G1 3 trials · 5 incl. sub-types Sub-types →
- Colorectal neuroendocrine tumor G1 1 trial · 4 incl. sub-types Sub-types →
-
Rectum neuroendocrine neoplasm 3 trials · 6 incl. sub-types
2 sub-types
- Rectal neuroendocrine tumor 3 trials · 4 incl. sub-types Sub-types →
- Anal canal neuroendocrine neoplasm 1 trial Sub-types →
-
Colon neuroendocrine neoplasm 0 trials · 5 incl. sub-types
3 sub-types
- Neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor 0 trials · 5 incl. sub-types Sub-types →
- Appendix neuroendocrine neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Colon small cell neuroendocrine carcinoma 0 trials
Most studied deeper sub-types
-
New drug shows promise in slowing rare carcinoid tumors
Disease control OngoingThis study tested a drug called pazopanib in 171 people with carcinoid tumors that were growing or spreading. The goal was to see if pazopanib could slow tumor growth better than a placebo. Participants were randomly assigned to receive either pazopanib or a placebo, and research…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New chemo combo tested for rare gut cancers – results disappoint
Disease control OngoingThis phase 2 trial tested whether a combination of temozolomide and capecitabine works better than the standard cisplatin and etoposide for people with advanced, hard-to-treat gastrointestinal neuroendocrine carcinomas. The study enrolled 67 participants whose cancer had spread o…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could abemaciclib be the next weapon against Hard-to-Treat gut tumors?
Disease control OngoingThis phase 2 trial tests the drug abemaciclib (Verzenio) in 20 patients with advanced gastroenteropancreatic neuroendocrine tumors that have spread, are not responding to treatment, and cannot be surgically removed. The drug works by blocking enzymes that help cancer cells grow. …
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC